Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX 5 25 SULFITE FREE IN DEXTROSE 25 IN PLASTIC CONTAINER versus KABIVEN IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX 5 25 SULFITE FREE IN DEXTROSE 25 IN PLASTIC CONTAINER versus KABIVEN IN PLASTIC CONTAINER.
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER vs KABIVEN IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% is a parenteral nutrition solution providing amino acids (5%) and dextrose (25%) for caloric and protein requirements. Amino acids serve as substrates for protein synthesis and other metabolic processes; dextrose provides calories to spare protein catabolism. No single molecular target.
Kabiven is a parenteral nutrition formulation that provides a balanced mixture of amino acids, dextrose, and lipids to meet nutritional requirements. The amino acids serve as building blocks for protein synthesis, dextrose provides a carbohydrate source for energy, and lipids supply essential fatty acids and additional energy. Electrolytes are included to maintain fluid and electrolyte balance.
Intravenous infusion. Dose is individualized based on protein and calorie requirements. For adults, typical amino acid dose is 0.8-1.5 g/kg/day, with dextrose providing 25% concentration. Rate adjusted to meet metabolic needs, usually 1-2 mL/kg/hour.
Intravenous infusion. Adult dose based on nutritional needs: typically 0.8-1.5 g amino acids/kg/day, 0.8-1.5 g lipids/kg/day, and 2-4 g dextrose/kg/day. Maximum infusion rate: 1.7 mL/kg/hour (Kabiven Peripher) or 2.6 mL/kg/hour (Kabiven Central).
None Documented
None Documented
Not applicable as a metabolic substrate; terminal half-life of dextrose is ~2 hours for glucose clearance; amino acids have variable half-lives of 0.3–2.5 hours based on individual amino acid metabolism and utilization.
Variable; amino acids: 0.5–1 h; lipids: 0.5–1 h (intralipid clearance); glucose: rapid. No true terminal half-life as a mixture.
Renal elimination of amino acids and dextrose metabolites; virtually 100% renal excretion of dextrose metabolites (e.g., CO2) and amino acid nitrogen (as urea), with <2% biliary/fecal.
Renal: <3% unchanged; primarily metabolized via protein catabolism; nitrogen excretion is renal (urea, ammonia); fat emulsion components are cleared by the reticuloendothelial system and metabolized. Biliary/fecal: negligible.
Category C
Category C
Parenteral Nutrition
Parenteral Nutrition